🧬 CMV Vaccine Tracker Dashboard

Updated July 2026. Tracking cytomegalovirus (CMV) vaccine development to prevent congenital CMV infection, the leading infectious cause of birth defects worldwide. CMV affects 1 in 200 babies (0.5-0.7% of all births), causing permanent disabilities including hearing loss, vision impairment, intellectual disability, and cerebral palsy. Major setback: Moderna announced on October 22, 2025 that its lead candidate mRNA-1647 did not meet its primary endpoint in the Phase 3 CMVictory trial — vaccine efficacy was 6–23% depending on case definition, well below target — and the company has discontinued its congenital CMV development program. Moderna continues to evaluate mRNA-1647 in a Phase 2 trial for CMV reactivation in bone marrow transplant patients (expected to end August 2026). GSK's gB/MF59 remains the most advanced congenital-prevention candidate. This tracker monitors the complete CMV vaccine pipeline targeting maternal immunization, transplant recipients, and congenital infection prevention.